A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

  • STATUS
    Recruiting
  • End date
    Dec 22, 2033
  • participants needed
    500
  • sponsor
    AHS Cancer Control Alberta
Updated on 22 April 2021
cancer
somatostatin
metastasis
progressive disease
positron emission tomography
18f-fdg
dotatate
neuroendocrine tumor
carcinoid
l-arginine
pet-ct scan
peptide receptor radionuclide therapy
lu-dota-tate

Summary

Neuroendocrine tumours (NETs) are rare, slow growing, and diagnosis is often delayed with advanced metastases at presentation. In select patient populations, radioisotope therapy with Lutetium-177 (Lu-DOTA-TATE) has been shown to be a safe and effective palliative therapy, and has been widely used by research groups in Europe. A brand of Lu-DOTA-TATE (Lutathera(R)) is approved for the treatment of gastroenteropancreatic NETs in Europe, the U.S., and more recently in Canada. While Lutathera(R) is approved in Canada, it is not publicly funded in Alberta. Lu-DOTA-TATE has been used at the Cross Cancer Institute to treat more than 300 patients with NETs since August, 2010. Our Lu-DOTA-TATE treatment was initially given under Health Canada's Special Access Programme (SAP), with each individual treatment requiring separate approval. In 2014, Health Canada requested we conduct a clinical trial with Lu-DOTA-TATE instead.

The purpose of this study is to: 1) assess the efficacy of Lu-DOTA-TATE treatment in patients with somatostatin receptor positive tumours; 2) assess the safety of Lu-DOTA-TATE; 3) assess the effect of Lu-DOTA-TATE on Quality of Life and survival.

Description

The proposed clinical trial will be a Phase II, open label, single site study in subjects with somatostatin receptor positive tumours. Radioactive Lu-DOTA-TATE doses are fixed within a range of 1.85 - 5.55 GBq 10%, with individual doses based on specified risk factors. There will be two groups of subjects enrolled in this study. Group A subjects (primary therapy) will have progressive somatostatin receptor positive tumours and have never received Lu-DOTA-TATE. Group B subjects (maintenance therapy) will be those subjects who have previously received Lu-DOTA-TATE under the Special Access Programme (SAP) and will maintain their treatment schedule when they are entered into the study.

All subjects in Group A will be treated in an induction stage using 10-14 week dosing for up to 4 treatments. If an individual patient shows stable or improving disease status with no significant toxicities after the 4 induction treatments, they will be assessed 12-20 weeks after the last therapeutic treatment for entry into the maintenance stage. Patients will be re-assessed for stable or improving disease status with no significant toxicities 12-20 weeks after every other treatment of the maintenance stage for consideration of further maintenance treatments (re-evaluations), up to a maximum of 8 treatments per patient if there have been no significant toxicities or progression. At each treatment, an amino acid solution is infused prior to and during the Lu-DOTA-TATE infusion to protect the kidneys. Subjects will be followed for 6 months and 1 year ( 4 weeks) following their last treatment dose to determine progression-free survival, and for 2, 3, and 5 years ( 4 weeks) following their last treatment dose to determine overall survival. All subjects meeting evaluation criteria will be analysed for safety, and all Group A subjects who have received at least two treatments of Lu-DOTA-TATE will be evaluated for efficacy. Those Group B subjects with adequate baseline data for comparison collected retrospectively from a chart review study (REV-LUT-001) may also be evaluated for safety and efficacy. Additional optional characterization of tumour samples from subjects who have had surgery before or during the study may be performed to characterize NET tumour biology changes following Lu-DOTA-TATE treatment.

Details
Condition Neuroendocrine carcinoma, Neuroendocrine carcinoma
Treatment [177]Lu-DOTA-TATE
Clinical Study IdentifierNCT01876771
SponsorAHS Cancer Control Alberta
Last Modified on22 April 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female 14 - 90 years of age
Presence of somatostatin receptor positive tumour(s) on radionuclide imaging, with uptake greater than liver background as assessed by planar Octreoscan images or Ga-68 labelled somatostatin analogue (68Ga-DOTATATE or 68Ga-HA-DOTATATE) PET imaging, with at least 1 tumour site reliably evaluable by CT or magnetic resonance imaging (MRI) of at least 1.0 cm (smallest dimension) or >1.5 cm lymph node disease (smallest dimension) (the target lesion) within 26 weeks of enrolment
Histologically confirmed diagnosis of neuroendocrine tumor
Progressive disease documented by anatomic imaging and/or presence of new lesions on somatostatin receptor imaging assessed by comparable studies. In the opinion of the investigator, patients with no progression on imaging may still be considered eligible in presence of carcinoid symptoms refractory to treatment with somatostatin receptor analogues
18F-FDG PET/CT whole-body imaging within 26 weeks of enrolment
Life expectancy greater than 12 weeks from enrollment
Serum creatinine 150 mol/L, and a calculated (Cockcroft-Gault) or estimated GFR of 50 mL/min measured within 2 weeks of enrollment
Haemoglobin concentration 90 g/L; white blood cell (WBC) count 2 x 10^9/L; platelets 100 x 10^9/L measured within 2 weeks of enrolment
Liver function tests (total bilirubin, alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase) 3X the limit of normal measured within 2 weeks of enrolment. Serum albumin 23 g/L within 2 weeks of enrolment
Eastern Cooperative Oncology Group (ECOG) Performance Scale Score 2 measured within 2 weeks of enrolment
Provide written informed consent prior to enrolment
Group B (Maintenance Therapy) Inclusion Criteria
Male or female 14 - 90 years of age
Have previously received Lu-DOTA-TATE treatment under the SAP
Life expectancy greater than 12 weeks from enrolment
Serum creatinine 150 mol/L, and a calculated (Cockcroft-Gault) or estimated glomerular filtration rate (GFR) of 50 mL/min measured within 2 weeks of enrolment
Haemoglobin concentration 90 g/L; white blood cell (WBC) count 2 x 10^9/L; platelets 100 x 10^9/L measured within 2 weeks of enrolment
Liver function tests (total bilirubin, alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase) 3X the limit of normal measured within 2 weeks of enrolment. Serum albumin 23 g/L within 2 weeks of enrolment
Eastern Cooperative Oncology Group (ECOG) Performance Scale Score 2 measured within 2 weeks of enrolment
Provide written informed consent prior to enrolment

Exclusion Criteria

Have previously received Lu-DOTA-TATE therapy
Potential for surgery with curative intent. Local surgery for symptomatic relief permitted as long as target lesion unaffected
Surgery within 12 weeks of enrolment. Surgery for removal of superficial skin lesions, laser eye surgery, or cataract surgery is permitted
Liver embolization [transcatheter arterial embolization (TAE), TACE, or TARE] within 4 weeks of enrolment
Radioisotope therapy within 12 weeks of enrolment
Systemic therapy: mTOR inhibitors and tyrosine kinase inhibitors within 6 weeks of enrolment; chemotherapy and interferon within 8 weeks of enrolment
Change in long acting somatostatin analogues, dosage, or dosage frequency within 12 weeks of enrolment
Localized external beam irradiation with target lesion(s) in the radiation field. Other localized external beam therapy is permitted
Known brain metastases unless these metastases have been treated and stabilized (confirmed by CT) for 4 months prior to enrolment
Uncontrolled diabetes mellitus defined as random glucose 2X the upper limit of normal (or HbA1c > 10%, if results available) within 12 weeks of enrolment
Another significant medical, psychiatric or surgical condition uncontrolled by treatment, which may interfere with completion or conduct of the study (such as urinary incontinence, co-existing malignancies)
Pregnancy
Breast feeding
Prior radiation therapy to more than 25% of the bone marrow
If, in the opinion of the investigator, other treatments are considered more appropriate than the investigational therapy, based on patient and disease characteristics
Group B (Maintenance Therapy) Exclusion Criteria
Another significant medical, psychiatric or surgical condition uncontrolled by treatment, which may interfere with completion or conduct of the study (such as urinary incontinence or co-existing malignancies)
Pregnancy
Breast feeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note